WO2004024881A3 - LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE - Google Patents

LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE Download PDF

Info

Publication number
WO2004024881A3
WO2004024881A3 PCT/US2003/028902 US0328902W WO2004024881A3 WO 2004024881 A3 WO2004024881 A3 WO 2004024881A3 US 0328902 W US0328902 W US 0328902W WO 2004024881 A3 WO2004024881 A3 WO 2004024881A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathway
methods
ldlrs
modifiers
modulators
Prior art date
Application number
PCT/US2003/028902
Other languages
French (fr)
Other versions
WO2004024881A2 (en
Inventor
Michael Costa
Mark E Maxwell
Mark R Lackner
Tak Hung
Carol L O'brien
Kim Lickteig
Original Assignee
Exelixis Inc
Michael Costa
Mark E Maxwell
Mark R Lackner
Tak Hung
Carol L O'brien
Kim Lickteig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Michael Costa, Mark E Maxwell, Mark R Lackner, Tak Hung, Carol L O'brien, Kim Lickteig filed Critical Exelixis Inc
Priority to AU2003278811A priority Critical patent/AU2003278811A1/en
Publication of WO2004024881A2 publication Critical patent/WO2004024881A2/en
Publication of WO2004024881A3 publication Critical patent/WO2004024881A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Abstract

Human LDLR genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of LDLR are provided.
PCT/US2003/028902 2002-09-16 2003-09-15 LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE WO2004024881A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003278811A AU2003278811A1 (en) 2002-09-16 2003-09-15 LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41098802P 2002-09-16 2002-09-16
US60/410,988 2002-09-16

Publications (2)

Publication Number Publication Date
WO2004024881A2 WO2004024881A2 (en) 2004-03-25
WO2004024881A3 true WO2004024881A3 (en) 2004-07-01

Family

ID=31994232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/028902 WO2004024881A2 (en) 2002-09-16 2003-09-15 LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

Country Status (2)

Country Link
AU (1) AU2003278811A1 (en)
WO (1) WO2004024881A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020065229A1 (en) * 2000-11-29 2002-05-30 Davis Ashley Stuart Anti-S-phase tubulin ligands
US6407062B1 (en) * 1995-09-27 2002-06-18 St. Jude Children's Research Hospital ARF-P19, a novel regulator of the mammalian cell cycle

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407062B1 (en) * 1995-09-27 2002-06-18 St. Jude Children's Research Hospital ARF-P19, a novel regulator of the mammalian cell cycle
US20020065229A1 (en) * 2000-11-29 2002-05-30 Davis Ashley Stuart Anti-S-phase tubulin ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JACKSON-GRUSBY ET AL: "Loss of genomic methylation cases p53-dependent apoptosis and epigenetic deregulation", NATURE GENETICS, vol. 27, January 2001 (2001-01-01), pages 31 - 39, XP002975926 *

Also Published As

Publication number Publication date
WO2004024881A2 (en) 2004-03-25
AU2003278811A1 (en) 2004-04-30
AU2003278811A8 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
WO2003073823A3 (en) PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002099053A3 (en) Slc22as as modifiers of the p53 pathway and methods of use
WO2002098356A3 (en) Ppp2cs as modifiers of the p53 pathway and methods of use
WO2003014301A3 (en) Hprp4s as modifiers of the p53 pathway and methods of use
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2002099043A8 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2003035831A3 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2004065542A3 (en) MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004015071A3 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004024881A3 (en) LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2003074673A3 (en) Lgals as modifiers of the chk pathway and methods of use
WO2003074677A3 (en) MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
WO2004015069A3 (en) MP2153S AS MODIFIERS OF THE p21 OR p53 PATHWAY AND METHODS OF USE
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2004061123A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003052068A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003066811A3 (en) Msrebps as modifiers of the srebp pathway and methods of use
WO2003052066A3 (en) Klcs as modifiers of the p53 pathway and methods of use
WO2004104168A3 (en) Mrbs as modifiers of the rb pathway and methods of use
WO2005003306A3 (en) Sppls as modifiers of the p53 pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP